Non-Small Cell Lung Cancer - Metastatic

Recurrent or Metastatic (IIIb, IV)

1st line

2nd/3rd line

Correlatives

IRB# 9059 Lung Cancer Mutation Consortium

Squamous

IRB# 11851
GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of MPDL3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin+Paclitaxel Or MPDL3280a In Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel In Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

Non-squamous

IRB# 11845
GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of MPDL3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin+Paclitaxel Or MPDL3280a In Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel In Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

IRB# 11740 Tiger 3: Rociletinib Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR

IRB# 111046 Lung-MAP: Study involving multiple drugs

Key

Open for Enrollment
Enrollment on Hold
In Development

8/17/2016
www.ohsu.edu/cancer